scispace - formally typeset
A

Aparajita Chowdhury

Researcher at University of Nebraska Medical Center

Publications -  7
Citations -  237

Aparajita Chowdhury is an academic researcher from University of Nebraska Medical Center. The author has contributed to research in topics: Centrosome & Cell cycle checkpoint. The author has an hindex of 5, co-authored 7 publications receiving 212 citations.

Papers
More filters
Journal ArticleDOI

Inorganic arsenic: A non-genotoxic carcinogen.

TL;DR: The data strongly supports a non-linear dose response for the effects of inorganic arsenic, and in various in vitro and in vivo models and in human epidemiology studies there appears to be a threshold for biological responses, including cancer.
Journal ArticleDOI

KIBRA regulates aurora kinase activity and is required for precise chromosome alignment during mitosis.

TL;DR: It is proposed that the KIBRA-Aurora-Lats2 protein complexes form a novel axis that regulates precise mitosis, which is consistent with playing a role in mitosis.
Journal ArticleDOI

Identification of a Novel TGFβ/PKA Signaling Transduceome in Mediating Control of Cell Survival and Metastasis in Colon Cancer

TL;DR: This work demonstrates for the first time that TGFβ receptor reconstitution leads to decreased metastatic colonization and indicates the clinical potential for developing anti-metastasis therapy based on inhibition of this very important aberrant cell survival mechanism by the multifaceted TGF β/PKA transduceome induced pathway.
Journal ArticleDOI

Histone Deacetylase Inhibitor Belinostat Represses Survivin Expression through Reactivation of Transforming Growth Factor β (TGFβ) Receptor II Leading to Cancer Cell Death

TL;DR: Patients exhibiting high survivin expression with epigenetically silenced TGFβRII with concomitant survivin repression may represent a significant mechanism in the anticancer effects of this drug, and might potentially benefit from the use of this histone deacetylase inhibitor.
Journal ArticleDOI

A novel Aurora kinase A inhibitor MK-8745 predicts TPX2 as a therapeutic biomarker in non-Hodgkin lymphoma cell lines.

TL;DR: It is demonstrated that treatment with MK-8745 leads to cell cycle arrest at the G2/M phase with accumulation of tetraploid nuclei followed by cell death in non-Hodgkin lymphoma (NHL) cell lines, and results indicate that TPX2 may serve as a biomarker for identifying subpopulations of patients sensitive to Aurora-A inhibitor treatment.